Likuiditas cepet PharmaCyte Biotech (PMCB)

This daily price chart for PharmaCyte Biotech (PMCB) on GURU.Markets reflects the asset's dynamics, where the separate_ratio_quick indicator stands at 38.80. PharmaCyte Biotech focuses on developing cell-based therapies to combat diabetes and pancreatic tumors, targeting major oncology centers. The development strategy relies on the commercialization of live-cell encapsulation systems for the treatment of solid tumors. The business currently depends on investment as the product is undergoing clinical trials.

PharmaCyte Biotech (PMCB) lacks regular revenue, meaning its survival depends on the efficiency of attracting external capital. The quick ratio measures the company's ability to meet short-term obligations using only cash and accounts receivable, excluding inventory. For a biotech firm, this liquidity surplus serves as a safety buffer between funding rounds. By analyzing the quick ratio trend, an investor assesses the risk of bankruptcy or inefficiencies in reserve management.